AI
Monday, March 31, 2025 1:26:52 AM
zero82,
Thanks for repeatedly reposting your free advice on when we should sell our shares 😶
I actually think we might be capable of doing our own research, identifying trustworthy sources, and making independent decisions. ✅️
The statement by “Investor082” is more than 99% conjecture, lacking factual basis and logical reasoning. The author’s claims are unsubstantiated and highly questionable.
Evaluation of the Claims
The quoted statement makes speculative and unsupported assertions about NWBO’s future, framed as certainty rather than opinion. The author has a pattern of repeatedly posting similar messages, urging shareholders to sell based on broad, negative assumptions about the company’s management and prospects. This approach is consistent with tactics commonly seen in “short and distort” campaigns, where misleading or exaggerated claims are used to undermine investor confidence and suppress share prices.
Below is an objective breakdown of why the statement lacks credibility, financial rationale, and factual support.
1. Unsupported Predictions and False Certainty
• The post makes definitive claims about regulatory outcomes in multiple jurisdictions (U.S., Canada, EU) without citing any verifiable sources. No regulatory agency, company disclosure, or independent analysis has indicated such conclusions.
• Predicting outcomes as far out as 2027–2030 is inherently unreliable. Market conditions, regulatory landscapes, and company strategies evolve, making rigid, long-term claims speculative at best.
2. Mischaracterization of Dilution and Financing
The post selectively focuses on share dilution while ignoring the broader financial picture:
• Raising capital through share issuance is a standard practice for biotech firms funding clinical trials and regulatory processes.
• NWBO’s financing strategy must be assessed in conjunction with potential revenue, partnerships, or licensing deals that could mitigate dilution effects.
• The claim that NWBO has “no money” to run trials contradicts the fact that the company has successfully funded multiple clinical studies and regulatory submissions.
3. Use of Fear Tactics and Loaded Language
• The statement employs emotionally charged language such as “lethargic execution” and “wiping off shareholder wealth” without providing factual support. These terms serve to create negative sentiment rather than inform investors with objective analysis.
• A particularly questionable claim is the suggestion that shareholders should sell on UK approval. This implies an intent to discourage investor confidence at a key inflection point, a hallmark of manipulative messaging.
4. Misrepresentation of Investment Strategy
The post presents a one-sided risk analysis while omitting key potential drivers of value:
• Regulatory milestones that could enhance valuation.
• Strategic partnerships that may provide non-dilutive funding.
• Scientific validation through peer-reviewed research supporting NWBO’s platform.
• The assertion that there is “no exit path” without a big pharma deal is misleading. Investors have multiple potential value realization scenarios, including organic revenue growth, licensing agreements, or M&A activity.
Understanding “Short and Distort” Tactics
A “short and distort” campaign aims to drive a stock price lower by spreading misleading or exaggerated negativity. Warning signs include:
• Repetitive negative posts from the same author, regardless of company progress.
• Assertions of future failure stated as fact, without supporting evidence.
• Attempts to encourage panic selling at key corporate milestones.
Investor Advisory: Rely on Verifiable Sources
Investors should be cautious of anonymous online claims, especially those that exhibit patterns of one-sided negativity. Reliable financial decisions should be based on:
• Regulatory filings (e.g., SEC disclosures), which are legally required to be truthful under penalty of law.
• Peer-reviewed scientific research, which undergoes independent expert evaluation.
• Licensed financial professionals, who are accountable to industry regulations.
Conclusion
The quoted statement is not a balanced or fact-based analysis—it’s a mix of:
• Speculative claims stated as certainty
• One-sided negativity that ignores key facts
• Attempts to undermine investor confidence ahead of key milestones
Investors should be skeptical of unverified online narratives and rely on reputable, fact-based sources such as regulatory filings, peer-reviewed research, and licensed financial professionals.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175992369
Thanks for repeatedly reposting your free advice on when we should sell our shares 😶
I actually think we might be capable of doing our own research, identifying trustworthy sources, and making independent decisions. ✅️
The statement by “Investor082” is more than 99% conjecture, lacking factual basis and logical reasoning. The author’s claims are unsubstantiated and highly questionable.
Evaluation of the Claims
The quoted statement makes speculative and unsupported assertions about NWBO’s future, framed as certainty rather than opinion. The author has a pattern of repeatedly posting similar messages, urging shareholders to sell based on broad, negative assumptions about the company’s management and prospects. This approach is consistent with tactics commonly seen in “short and distort” campaigns, where misleading or exaggerated claims are used to undermine investor confidence and suppress share prices.
Below is an objective breakdown of why the statement lacks credibility, financial rationale, and factual support.
1. Unsupported Predictions and False Certainty
• The post makes definitive claims about regulatory outcomes in multiple jurisdictions (U.S., Canada, EU) without citing any verifiable sources. No regulatory agency, company disclosure, or independent analysis has indicated such conclusions.
• Predicting outcomes as far out as 2027–2030 is inherently unreliable. Market conditions, regulatory landscapes, and company strategies evolve, making rigid, long-term claims speculative at best.
2. Mischaracterization of Dilution and Financing
The post selectively focuses on share dilution while ignoring the broader financial picture:
• Raising capital through share issuance is a standard practice for biotech firms funding clinical trials and regulatory processes.
• NWBO’s financing strategy must be assessed in conjunction with potential revenue, partnerships, or licensing deals that could mitigate dilution effects.
• The claim that NWBO has “no money” to run trials contradicts the fact that the company has successfully funded multiple clinical studies and regulatory submissions.
3. Use of Fear Tactics and Loaded Language
• The statement employs emotionally charged language such as “lethargic execution” and “wiping off shareholder wealth” without providing factual support. These terms serve to create negative sentiment rather than inform investors with objective analysis.
• A particularly questionable claim is the suggestion that shareholders should sell on UK approval. This implies an intent to discourage investor confidence at a key inflection point, a hallmark of manipulative messaging.
4. Misrepresentation of Investment Strategy
The post presents a one-sided risk analysis while omitting key potential drivers of value:
• Regulatory milestones that could enhance valuation.
• Strategic partnerships that may provide non-dilutive funding.
• Scientific validation through peer-reviewed research supporting NWBO’s platform.
• The assertion that there is “no exit path” without a big pharma deal is misleading. Investors have multiple potential value realization scenarios, including organic revenue growth, licensing agreements, or M&A activity.
Understanding “Short and Distort” Tactics
A “short and distort” campaign aims to drive a stock price lower by spreading misleading or exaggerated negativity. Warning signs include:
• Repetitive negative posts from the same author, regardless of company progress.
• Assertions of future failure stated as fact, without supporting evidence.
• Attempts to encourage panic selling at key corporate milestones.
Investor Advisory: Rely on Verifiable Sources
Investors should be cautious of anonymous online claims, especially those that exhibit patterns of one-sided negativity. Reliable financial decisions should be based on:
• Regulatory filings (e.g., SEC disclosures), which are legally required to be truthful under penalty of law.
• Peer-reviewed scientific research, which undergoes independent expert evaluation.
• Licensed financial professionals, who are accountable to industry regulations.
Conclusion
The quoted statement is not a balanced or fact-based analysis—it’s a mix of:
• Speculative claims stated as certainty
• One-sided negativity that ignores key facts
• Attempts to undermine investor confidence ahead of key milestones
Investors should be skeptical of unverified online narratives and rely on reputable, fact-based sources such as regulatory filings, peer-reviewed research, and licensed financial professionals.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175992369
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
